#RedJournal #OpenAccess : Patterns of recurrence following metastasis directed therapy (MDT) in castration sensitive oligometastatic PCa favor bone recurrence; majority of patients will experience long term control or oligorecurrence following MDT ➡️ bit.ly/Deek2020 #pcsm

📣 Single fraction respiratory-gated lung SBRT delivered in overall 38 minutes using the MRIdian system!

#SoProud #MyTeam #MRgRT #SBRT #RadOnc #oligomets
ViewRay

Thanks ASTRO for the shout out! Online adaptation ⬆️ the therapeutic ratio of SBRT for abdominal oligomets ☢️ Here we showed that this is feasible on a CBCT-guided platform #ethos . One of many ways were are working to increase access to adaptive RT Wash U Radiation Oncology Lauren Henke, MD, MSCI

SBRT in PCa oligomets debate : for the motion Alison Tree 💙🇺🇦 going straight to the point! Cost effectiveness in favor of SBRT but we have still to convince the oncology community about that! 💪🏻💪🏻💪🏻

Long term results of a trial of SABR to lymph node and non-spine oligomets .

Excellent local control and 93%, very low toxicity and 20 Gy single fraction SABR appears safe.

#ESTRO23

'In the #RedJournal : CT-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of abdominal oligometastases was feasible in silico and dosimetrically superior to CT-guided non-adapted SBRT. Joshua Schiff Hayley Stowe, MD Alex Price ➡️ bit.ly/Schiff_2022 '

Cork University Hosp Radiation Oncology team on tour last week Princess Margaret Cancer Centre for their brilliant course on SABR & IGRT for Liver/pancreas/oligomets Claire Keating Aisling Barry

A 5-year-old boy insists to his mom that he has an 'identical' twin.

“He went on and on about how they looked exactly the same. We both have brown eyes, we both have dark hair,’ and he was just adamant …'

Read more:
theepochtimes.com/he-was-adamant…

📢 Recent update PhII TROG
Long-term FU no # safety/efficacy/or OS between 1FX vs mFX SABR in lung oligomets
💡 Key findings:
🔹 OS at 5.4 y FU: 51%
🔹 DSF at 5 y: 20%.
1FX was chosen based on cost-effectiveness. ✅ No # by fractionation #RAdonc congrats Shankar Siva👏👏

Gerry Hanna ESTRO Shankar Siva Fiona McDonald Aidan Cole Steven David Nick Hardcastle What GTV-CTV margin was used for bone oligomets, was it mentioned?

Shankar Siva TROG Cancer Research Matthias Guckenberger Gerry Hanna Piet Ost Dr. David Palma, MD PhD Søren M Bentzen ESTRO Daniel E Spratt Matthew Katz, MD 🇺🇸 💜 Todd Scarbrough I hope this trial begins to change practice. I’m sure many have initial hesitation if no 1-fx experience. Believe in the data and take the leap… 🙌 I did esp for multiple oligomets and haven’t looked back. Truly stellar work Shankar Siva 👏👏👏

GoLinks is the easiest way to share work resources, and it will never get lost in an e-mail inbox. It's what you need for your business. GoLinks makes it simple for people to get what they need efficiently.

Todd Aguilera MD PhD Dr. Nina Niu Sanford Dr. David Palma, MD PhD Ali Hosni @TAMERMR Laura Dawson Robert Timmerman
A series of SABR ttt PDAC oligomets (OPanc) (1-5 mets) published in Red Journal. Retro, small n & selection bias limiting, but SABR doubled OS with less time on CTH.
authors.elsevier.com/c/1fgzw1Hx52CH…

Excellent talk by Radiation Oncology Sunnybrook Health Sciences Centre rising star George J. Li (PI: Alex Louie MD, PhD) at #CARO2022 on #SABR #SBRT for ultra-central lung tumors #lcsm 🫁 #oligomets

Beautiful talk by Matthias Guckenberger at #WCI2021 yesterday, tacking oligomets dilemma with clarity of thought! Loved it!
Tata Memorial Centre TMC Breast DMG TMC Radiation Oncology Rima Pathak MD Revathy Krishnamurthy Rajiv Sarin MD Supriya Chopra

Challenging scenarios in oligomets. What number of Mets = oligo? Do you treat prostate OM diff from Colon?
How “hard” to look for Mets (ie how many imaging modalities) ? Does # of Mets matter as much as size ? #ESTRO2023

It's a competitive advantage to be underrated and underestimated. They don't pay attention to you until it's too late.

📢Breaking news from #ESTRO2023
✅CORE RCT ➡️SABR in 1-3 oligomets
✅Out of 245 pts, 220 had breast/prostate cancer
No # observed in Grade 3+ tox
PFS: HR = 0.79, with a 5-mo ⬆️ median PFS
🔚Findings suggest that combining SABR with SoC outperforms SoC alone ‼️‼️‼️ #radonc #SABR

.Patrick Cheung MD (@Sunnybrook) at #SABRCAN22 ☢️🇨🇦

Future #SBRT domains:
high risk dz?
micromet/clinically + nodes?
MR-Linac guided?
SBRT boost instead of HDR?(@DrAndrewLoblaw ASCENDE-SBRT pending accrual)

Q for oligomets in CSPC:
MDT w/ ADT (PR.20) or to delay (@piet_ost)

Syed A. Ahmad @halletjulie Flavio G Rocha, MD, FACS, FSSO Sepideh Gholami, MD, MAS, FACS, FSSO @LeeOcuin Hop S. Tran Cao Patrick Lorimer, MD Susanne Warner Natalie Coburn Niraj J. Gusani, MD 🇺🇸 Matt Dixon Motaz Qadan, MD, PhD Callisia Clarke MD Mary Dillhoff MD Alexandra Gangi, MD SoMe4HPB Some4MDT Jash Datta Gregory C. Wilson Superselect pts with PDAC for 'aggressive therapy X' on the basis of indolent behavior, watch as superselected pts do sort of OK, then generalize that 'aggressive therapy X' is effective for patients with PDAC. Haven't reviewed this study but see: LAPC, IRE, oligomets, etc etc...

Longer OS, PFS, and time to start chemo/hormones (SCT) when SBRT is administered to oligomets compared to oligoprogression or to the dominant tumor (CDT) in mBC👇

➡️Timing of SBRT matters❗️
But…are these results reflective of patients’ selection or a Tx effect?🤔

#breastcancer

Time to launch radical prostatectomy trials in oligoMets disease ! francois rozet Jb Beauval EAU Young Academics Giorgio Gandaglia @ABrigantiMD AFU

Our 2nd paper re: MDT for oligometastatic #prostateCancer ,
Mayo Clinic Radiation Oncology & Johns Hopkins Kimmel Cancer Center team finds:

⚡️PATTERNS OF RECURRENCE:
Oligomets proportionally recur more in bone

⚡️MODES OF PROGRESSION:
Post-MDT, most pts are class I or II

💪🏽Mentorship by Drs. Bradley Stish, Deek, Tran etal

Paradigms change over time!

Tour de force from David Palma👏🏼

Oligomets & RT at #ASTRO21

Great job Shanka. Waterfall of lung oligomets with SABR/pembro. #WCLC19